Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Optinose Inc (OPTN) has issued an announcement.
OptiNose, Inc. has announced the FDA’s approval of its drug XHANCE for treating chronic rhinosinusitis in adults, a significant milestone for those tracking the pharmaceutical sector. Following this approval, the company is now tasked with conducting a study on the drug’s effects in children aged 12 to 17, with a deadline to initiate the study by the end of 2024 and complete it by early 2028, ensuring XHANCE’s safety and efficacy across a broader age range. This development could impact OptiNose’s market position and investor interest.
For a thorough assessment of OPTN stock, go to TipRanks’ Stock Analysis page.